GSK (GSK) announced positive phase III data from its clinical program to develop a next-generation version of its metered dose inhaler, Ventolin. Data confirm that the formulation of salbutamol MDI containing an innovative low carbon propellant HFA-152a shows therapeutic equivalence and is comparable in safety to salbutamol MDI containing the current propellant, HFA-134a. The findings will support regulatory submissions for the next-generation version, with launch expected from 2026, an important advance to bringing a more sustainable option to patients with respiratory disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Trump admin prepares new probe into U.S. pharma prices, FT says
- GSK announce EMA CHMP issued positive opinion for Shingrix in prefilled syringe
- Spero Therapeutics, GSK announce PIVOT-PO trial efficacy and safety results
- GSK treatment of malignant glioma designated for FDA orphan status
- ViiV Healthcare announces 96-week data from PASO DOBLE on Dovato